Compare ELTK & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTK | MREO |
|---|---|---|
| Founded | 1970 | 2015 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 67.5M |
| IPO Year | 1998 | 2017 |
| Metric | ELTK | MREO |
|---|---|---|
| Price | $8.54 | $0.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 3.2K | ★ 1.4M |
| Earning Date | 03-09-2026 | 03-19-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | $16.18 | $6,756.00 |
| Revenue Next Year | N/A | $38.65 |
| P/E Ratio | $48.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.65 | $0.20 |
| 52 Week High | $12.19 | $2.94 |
| Indicator | ELTK | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 36.24 | 38.00 |
| Support Level | $8.38 | $0.35 |
| Resistance Level | $9.19 | $0.42 |
| Average True Range (ATR) | 0.18 | 0.03 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 13.87 | 32.16 |
Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. It manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. Its geographic areas are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).